Kornimate/medical-research-clean huggingface dataset:
a study of oseltamivir (tamiflu) for treatment of influenza in immunocompromised participants.

Conditions: Influenza, Human

Summary: this 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the development of resistant influenza virus. eligible immunocompromised participants with laboratory-confirmed influenza will be randomized to receive either conventional dose (30 milligrams \[mg\] to 75 mg twice daily orally \[po\], depending on age and weight) or double dose (60 mg-150 mg twice daily po depending on age and weight) olseltamivir for 10 days. nasal and throat swabs will be taken, and safety evaluations made, at intervals during the study. the anticipated time on study medication is 10 days and the anticipated time on study is 40 days.


Eligibility criteria:
inclusion criteria: * rapid diagnostic test, pcr, or viral culture positive for influenza in the 96 hours prior to first dose * immunocompromised participants with primary or secondary immunodeficiency * symptoms suggestive of influenza-like illness * use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding exclusion criteria: * influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization * antiviral treatment for influenza in 2 weeks prior to randomization * severe hepatic impairment * any current renal replacement therapy * any gastrointestinal disorders which may interfere with the absorption of oseltamivir * participation in a study with an investigational drug from 4 weeks prior to study start until study end
effect of systemic oxygen on corneal epithelial wound healing in diabetic patients undergoing pars plana vitrectomy

Conditions: Corneal Diseases

Summary: 1. to compare the corneal epithelial defect healing time between diabetic patients receiving and not receiving supplementary oxygen after vitrectomy. 2. to determine whether factors such as age, duration of diabetes, duration of surgery and level of glycemic control have any influence on corneal epithelial wound healing time in diabetic patients receiving and not receiving supplementary oxygen post-vitrectomy.

this study aims to determine whether systemic oxygen therapy delivered through face mask would have beneficial effects on the healing of corneal epithelial wound in post-vitrectomy diabetic patients. it will be a prospective, randomised interventional clinical study conducted on diabetic patients indicated for vitrectomy. rationale of this study is to see if systemic oxygen delivered via face mask will hasten the resolution of corneal epithelial defects, which may either be iatrogenic (surgically-induced intra-operatively to enable clearer visualisation for the surgeon) or spontaneous (due to corneal epithelial fragility which is commoner in diabetics)

Eligibility criteria:
inclusion criteria: * diabetic patients aged 18 years and above planned for pars plana vitrectomy that required intra-operative corneal epithelial debridement to allow better surgical visualisation of the fundus were recruited within the study duration exclusion criteria: * pre-existing ocular surface or corneal disease, recent eye surgery within one month from the vitrectomy, glaucoma and if the patients have any contraindications to oxygen therapy (e.g. chronic obstructive pulmonary disease).

Keywords: epithelium, cornea, diabetes, vitrectomy, oxygen
superficial cervical plexus block for ijcl pain management

Conditions: Superficial Cervical Plexus Block; Pain

Summary: this is a prospective randomized trial evaluating the effect of scpb on reported patient pain following ijcl placement as compared to local infiltrate.

the goal of this study is to determine if scpbs provide more pain control than local infiltrate of anesthetic for internal jugular venous cannulation. the investigators hypothesis that patients who receive the scpb will have a lower vas rating on average than those who receive local infiltration following internal jugular venous cannulation. to test this, the investigators will be approaching eligible patients for inclusion in a research study. if the patients consent, the patients will be randomly assigned the standard of care treatment or the scpb. the investigators will then ask the patients to rate pain following insertion of the central line. the investigators will also evaluate different aspects of the patient's hospital course to evaluate their outcomes.

Eligibility criteria:
inclusion criteria: * patients who are 18 years and older, and; * present to the akron general emergency department (main) between march 1, 2021 and december 1, 2022, and; * require ijvc as a part of their clinical care. exclusion criteria: * patients who are intubated; or * patients who undergo cpr; or * patients who have an allergy to lidocaine or bupivacaine; or * patients who have a contraindication to receiving a superficial cervical plexus block such as cellulitis over erb's point or the internal jugular vein, abnormal anatomy, or prior surgery to the area.

Keywords: superficial cervical plexus block pain management
l-citrulline and metformin in duchenne's muscular dystrophy

Conditions: Duchenne's Muscular Dystrophy (DMD)

Summary: the purpose of the study is to show that the intake of l-citrulline and metformin improves muscle function and delay of progression in patients with duchenne's muscular dystrophy.

this is a single center, randomized, double-blind, placebo controlled study. the study medication consists of l-citrulline and metformin, respectively placebo given orally; 2.5 g l-citrulline or placebo will be given 3 times daily, metformin containing 250 mg or placebo will be administered 3 times daily. the duration of the study is 26 weeks and comprehends one screening and three study visits. amendment 1: amended eligibility criteria

Eligibility criteria:
inclusion criteria: * molecular diagnosis of dmd * patients 6.5 - 10 years of age at time of screening * ambulant * ability to walk 150 m in the 6 min walking distance (6mwt) * d1 subdomain of the mfm scale \>40% * stable treatment with steroids for \>6 months or steroid naïve patients exclusion criteria: * previous (3 months or less) or concomitant participation in another therapeutic trial * use of l-citrulline, l-arginine or metformin within the last 3 months * known individual hypersensitivity to l-citrulline or metformin * known or suspected malignancy * other chronic disease or clinical relevant limitation of renal, liver, heart function according to discretion of investigator * start of cortisone treatment or change in dosage \<6 months prior to screening

Keywords: duchenne's muscular dystrophy dmd
florbetapir f 18 pet imaging of beta-amyloid in parkinson's disease patients

Conditions: Parkinson's Disease

Summary: the primary aim of this study is to compare regional amyloid burden in parkinson's disease (pd) to normal control subjects. we hypothesize that there will be significant differences in overall amyloid burden in pd patients compared to age-matched normal controls.


Eligibility criteria:
inclusion criteria: * subjects may be enrolled if they (inclusion criteria): * are males or females ≥60 years of age * meet research diagnostic criteria for parkinson's disease: * diagnosis of a parkinsonian syndrome * bradykinesia (slowness of initiation of voluntary movement with progressive reduction in speed and amplitude of repetitive actions) * at least one of the following: muscle rigidity, rest tremor, postural instability not due to visual, vestibular, cerebellar or proprioceptive causes * supportive criteria for diagnosis of pd (two or more required) * unilateral onset of symptoms and persistent asymmetry * rest tremor present * progressive illness * excellent response to levodopa with dyskinesias * levodopa response for 5 years or more * clinical course of 10 years or more * have the ability to lie flat and tolerate a 10 minute pet scan. exclusion criteria: * subjects may not be enrolled if any of the following are present (exclusion criteria): * history of repeated strokes, repeated head injury, definite encephalitis * use of neuroleptics at onset of symptoms * sustained remission * strictly unilateral feature persisting \> three years after onset * significant supranuclear gaze palsy * cerebellar, pyramidal and early severe autonomic findings * early severe dementia suggesting a diagnosis of dementia with lewy bodies (dlb) * imaging study showing structural abnormality that could explain parkinsonism * negative response to an adequate levodopa trial * current clinically significant psychiatric disease that prohibits providing informed consent or participation in the study * current clinically significant endocrine or metabolic disease, pulmonary, * women of childbearing potential who are not two or more years post menopausal or surgically sterilized * have received any investigational medications, or have participated in a trial with investigational medications within the last 30 days

Keywords: amyloid burden parkinson's disease florbetapir pet amyloid pet imaging
effect of traditional chinese medicine of severe covid-19

Conditions: Severe COVID-19

Summary: this study evaluated the effect of integrated traditional chinese and western medicine in the treatment of severe covid-19. the patients were randomly divided into experimental group and control group.

in this study, a multi center randomized controlled trial design was adopted, and the subjects were randomly divided into the experimental group and the control group. the control group was treated with western medicine conventional treatment plus traditional chinese medicine decoction simulant, while the experimental group was treated with traditional chinese medicine syndrome differentiation treatment decoction. the course of treatment was 14 days and the patients were followed up for 3 months. the clinical effect of integrated traditional chinese and western medicine treatment was evaluated from the aspects of 28 day mortality, 28 days without invasive mechanical ventilation, invasive mechanical ventilation rate, 28 days without icu stay, clinical stability time, length of hospital stay, quality of life, sofa score, etc., to clarify the clinical efficacy of integrated traditional chinese and western medicine treatment for severe covid-19 infection.

Eligibility criteria:
inclusion criteria: * accord with the diagnosis of severe/critical novel coronavirus infection; * age \> 18 years old; * tcm syndrome differentiation diagnosis by the attending physician or above or two attending physicians for diagnosis and consensus; * sign the informed consent form. exclusion criteria: * pregnant and lactating women; * trauma, hematological malignancies, various solid tumors and obstetric complications; * dementia, various mental patients and those who are unwilling to cooperate; * the patient is expected to die within the next 24 hours; * combined with neuromuscular diseases affecting respiratory and motor functions; * people who have been bedridden for a long time for various reasons; * clinical trial participants who are taking part in other intervention measures; * those who are known to be allergic to the therapeutic drugs in this study.

Keywords: traditional chinese medicine severe covid-19
study to evaluate the efficacy and safety of exenatide once-weekly injection compared to once-daily insulin in type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the objectives of this clinical trial are to compare the effects of exenatide once weekly and insulin glargine on blood glucose control, body weight, lipids, safety, and tolerability.


Eligibility criteria:
inclusion criteria: * present with type 2 diabetes mellitus * hba1c between 7.1% and 11.0% inclusive * body mass index (bmi) of \>18kg/m2 and \<35kg/m2, inclusive * treated with a stable dose regimen of either of biguanide (bg) alone, bg + thiazolidinedione (tzd), bg + sulfonylurea (su), or bg + tzd + su for 90 days prior to study start exclusion criteria: * have received chronic (\>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start. * have been treated with drugs that promote weight loss within 90 days prior to study start. * have been treated with drugs that directly affect gastrointestinal motility for \> 21 consecutive days within 90 days prior to study start. * have had prior exposure to exenatide bid or qw or participated in the clinical trial of exenatide bid or qw (including the case that the study drug was not administered). * have been treated for \>2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: insulin, dipeptidyl peptidase-4 (dpp-4) inhibitors, glp-1 analogs * have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication. * are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start. * have donated blood within 30 days prior to study start.

Keywords: diabetes; exenatide once weekly; byetta; glargine; lantus; amylin; lilly
second-generation drug-eluting stents in diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus

Summary: this is an investigator initiated randomized trial, performed under the auspices of the spanish society of cardiology. it is a multicenter, international, parallel, randomized 1:1 (amphilimus-eluting stents vs zotarolimus-eluting stents) clinical trial performed exclusively in patients with diabetes mellitus. the study has an "all-comers diabetics" design. the primary-endpoint is target lesion failure at 1-year follow-up (non-inferiority design) and the co-primary end-point is target lesion failure at 2-years follow-up (superiority-design).


Eligibility criteria:
inclusion criteria(must meet all): * patients ≥18 years who understands the nature of the study and provides written informed consent. * diagnosis of diabetes according to the american diabetes association diagnostic criteria (\*) * documented silent ischemia, stable angina, unstable angina, or myocardial infarction (with or without st elevation). * at least one de novo coronary lesion with stenosis of more than 50% in a vessel with a reference vessel diameter of 2.25 to 4.5 mm by visual estimation. coronary anatomy is suitable for pci (patients with potential cabg indication should be eligible for pci after a multidisciplinary evaluation in a heart team). exclusion criteria: * cardiogenic shock or resuscitation * comorbidity with anticipated life expectancy to 24 months * inability to consent due to mechanical ventilation * pregnant female patient * conditions that could preclude a minimal of 1 month of dapt (such as, but not limited to: severe liver failure, platelet count \<100,000 cells/mm3, recent gastrointestinal bleeding or history of bleeding diathesis or coagulopathy) * contraindication or known allergy to aspirin, heparin, p2y12 inhibitors, cobalt and/or chromium metal alloys, sirolimus or derivates, polyurethane, or contrast media (for contrast-media allergy, patients that might be safely and adequately pre-medicated should be allowed to enter the study). * currently enrolled in another clinical trial.

Keywords: coronary artery disease diabetes mellitus drug-eluting stents restenosis
women's health initiative study of cognitive aging

Conditions: Healthy

Summary: the women's health initiative study of cognitive aging (whisca) is a two-armed, randomized, placebo controlled, clinical trial designed to assess the efficacy of postmenopausal hormone therapy (ht) on age related changes in specific cognitive functions.

whisca is an ancillary study to the women's health initiative (whi) and the whi memory study (whims) and has enrolled 2303 women aged 66 to 84 years who did not meet the criteria for dementia. whisca is investigating the effects of hormone therapy on rates of change over time in memory, other aspects of cognition (language, attention, spatial ability), motor function, and mood. objectives * does ht protect against age-associated memory and cognitive longitudinal decline in women age 65 and older? * what is the rate of change in memory and other cognitive abilities in women receiving ht compared to women receiving placebo? * does the addition of progesterone to ht modify the effects of estrogen on memory and other cognitive abilities?

Eligibility criteria:
inclusion criteria: * enrolled in whims * at least 65 years old * not diagnosed with dementia exclusion criteria: * women younger than 65 years of age * have dementia * not enrolled in whims

Keywords: women, dementia, cognition. non-demented women at least age 65
evaluating the feasibility and acceptability of implementing a prep program in pr-concra (san juan, puerto rico)- part a

Conditions: HIV/AIDS

Summary: the target population for this project will be men-who-have-sex-with-men (msm) at high risk of hiv acquisition

225 high risk msm will be interviewed to understand the knowledge and acceptability of pre-exposure prophylaxis (prep) in this population in puerto rico. a 187 item questionnaire will administered which will evaluate socio-demographic information, sexual conducts, prep knowledge and prep acceptability.

Eligibility criteria:
inclusion criteria; study subjects who meet the following inclusion criteria will be considered for enrollment for part a: 1. age 21 years or older 2. understand and sign the informed consent form and willing to participate in the study 3. male or transgender female 4. has one of the following risk factors: * a high risk msm as defined by: * having unprotected sexual intercourse with at least two male partners in the past 6 months, or * diagnosed with an sti in the past 6 months. part a - exclusion criteria: subjects with any of the following will not be considered for enrollment in part a: 1. age younger than 21 years old 2. unable or unwilling to provide an informed consent 3. female gender at birth 4. do not meet the high risk criteria

Keywords: hiv prevention, high risk msm, prep
evaluate df-003 in ex vivo assays using peripheral blood mononuclear cell from subjects with rosah syndrome

Conditions: Unrecognized Condition

Summary: alpha-1 kinase (alpk1) has been reported as a potential causative gene for rosah syndrome. genetic variants including t237m have been found in rosah syndrome patients. our in-house study has found that t237m mutation leads to hyperactivity of alpk1, which may be the cause of the inflammatory syndromes found in rosah syndrome patients. we hypothesize that t237m mutation alpk1 cause rosah syndrome and an alpk1 inhibitor can be a potential therapy for treating this disease. to test our hypothesis, we designed an experiment in which ex vivo peripheral blood mononuclear cells (pbmcs) from rosah syndrome patients will be exposed to a potent alpk1 inhibitor (df-003) or placebo. we expect to see downregulation of activated inflammatory genes, chemokine/cytokines and acute phase proteins in the rosah syndrome patient samples that are exposed df-003.


Eligibility criteria:
inclusion criteria: * male or female aged over 18 * patient with rosah syndrome with the confirm t237m mutation exclusion criteria: * person under legal protection or under protectives measures * person unable to express consent * person in emergency situation (vital or not) * person infected by human immunodeficiency virus and/or hepatitis b virus and/or hepatitis c virus

Keywords: rosah syndrome.
a retrospective chart review of thirty three children who have received clinical treatment with either romiplostim or eltrombopag from 2009-2013

Conditions: Immune Thrombocytopenia

Summary: this is a retrospective analysis of children (≤21years old) who received clinical treatment with either romiplostim or eltrombopag at 2 medical centers from 2009-2013. the children included in this study were from weill medical college of cornell university, new york, new york and children's hospital orange county, orange, california


Eligibility criteria:
inclusion criteria: 1. all patients in this study had received prior treatments before the start of tpo treatment including corticosteroids, ivig, iv anti-d, and/or rituximab. exclusion criteria: 1. children who do not have itp

Keywords: immune thrombocytopenia (itp), thrombopoietin (tpo) agents, children, romiplostim and eltrombopag
cuatsm compared with placebo for treatment of als/mnd

Conditions: Amyotrophic Lateral Sclerosis

Summary: multicenter, randomized, double-blind, placebo controlled study to assess the tolerabilty and efficacy of cuatsm in patients with als/mnd. patients will be randomized 1:1 to cuatsm or placebo for 6 x 28-day cycles (24 weeks) of treatment.

patients will be randomized 1:1 to cuatsm or placebo for 6 x 28-day cycles (24 weeks) of treatment. study drug is administered orally, once a day in fasted state (before breakfast). assessments for safety (physical examination, vital signs, hematology, serum chemistry adverse events) will be conducted at baseline and following each cycle of treatment. assessments for efficacy (revised als functional rating scale \[aslfrs-r\] score, and edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen \[ecas\] score, and seated slow vital capacity \[svc\]) will be conducted at baseline and following 2, 4 and 6 cycles of treatment. analysis of covariance (ancova) will be used to compare efficacy endpoints between cuatsm and placebo groups.

Eligibility criteria:
inclusion criteria: * signed informed consent * familial or sporadic als/mns by awaji-shima consensus recommendations * not taking riluzole or on stable dose of riluzole for 4 weeks prior to screening visit * no prior exposure to agents other than riluzole for treatment of als * adequate bone marrow reserve, renal and liver function * women of childbearing potential must have a negative pregnancy test and be non-lactating * women and men with partners of childbearing potential must take effective contraception while on treatment exclusion criteria: * presence of a gastrointestinal disorder (eg, malabsorption) that might jeopardize intestinal absorption of study drug * inability to perform seated svc * known immune compromising illness or treatment * drug abuse or alcoholism * clinically significant or active cardiovascular disease * acute or chronic infection * diagnosis of malignancy within 2 years prior to screening * dementia that may affect patient understanding and/or compliance with study requirements and procedures * current use of strong inducers or inhibitors of cyps 2c19 and 2d6 * current us of medications (other than riluzole) that are metabolized predominantly by cyp 1a2